发明授权
- 专利标题： COMBINATION OF AGENTS FOR INHIBITING TRANSPLANT REJECTION
- 专利标题（中）： 组合活性物质以防止其移植
-
申请号： EP01942118.9申请日： 2001-06-08
-
公开(公告)号： EP1294391B1公开(公告)日： 2012-08-15
- 发明人: TOWNSEND, Robert, M. , TODDERUD, Charles, Gordon , PEACH, Robert, J.
- 申请人： Bristol-Myers Squibb Company
- 申请人地址： Lawrenceville-Princeton Road P.O. Box 4000 Princeton NJ 08543-4000 US
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： Lawrenceville-Princeton Road P.O. Box 4000 Princeton NJ 08543-4000 US
- 代理机构： Reitstötter - Kinzebach
- 优先权： US210671P 20000609
- 国际公布： WO2001095928 20011220
- 主分类号： A61K38/17
- IPC分类号： A61K38/17 ; A61K39/395 ; C07K16/28 ; A61P37/06
摘要：
The invention provides methods for regulating cell-mediated immune responses, immune system diseases and allograft transplant rejection by interfering with the interaction of at least three different cell surface molecules with their natural ligands. A first cellular interaction is mediated by CD28/B7/CTLA4, a second interaction is mediated by CD40/CD154, and a third interaction is mediated by LFA-1 interaction with its ligands. Regulation of a cell-mediated immune response affects immune system diseases such as those associated with allograft transplantation.
公开/授权文献
信息查询
IPC分类:
